PMID- 28258390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2193-8261 (Print)
IS  - 2193-6544 (Electronic)
IS  - 2193-6544 (Linking)
VI  - 6
IP  - 1
DP  - 2017 Jun
TI  - Management of Hypertension Using Olmesartan Alone or in Combination.
PG  - 13-32
LID - 10.1007/s40119-017-0087-5 [doi]
AB  - Hypertension is one of the most significant and consistent risk factors for many 
      cardiovascular diseases. The global prevalence of hypertension has dramatically 
      increased over recent years. Life-style and genetic factors are generally 
      considered to be primarily responsible for the incidence of hypertension. 
      Concerning the high morbidity rate, setting up an updated standard for 
      hypertensive patients becomes indispensable. According to the widely accepted 
      standard treatments for hypertension, these four basic principles should be taken 
      into account: low dosage; medication should provide long term-control; 
      combination therapies are becoming common; personalized treatments are a newer 
      approach. In most patients with hypertension, adequate control of BP can be 
      achieved with combined therapy. Therefore, antihypertensive agents with 
      complementary mechanisms are now recommended. In this review, we focus on the 
      pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan 
      medoxomil, either alone or in combination with other antihypertensive 
      medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor 
      blocker with an excellent efficacy in the reduction and stabilization of blood 
      pressure. When combined with calcium channel blockers (CCBs) and diuretics, 
      olmesartan medoxomil has a better effect on controlling BP and reducing AEs in 
      patients.
FAU - Zhang, Xiaoshen
AU  - Zhang X
AD  - Department of Cardiology, Shanghai Tenth Hospital of Tongji University, Shanghai, 
      200072, China.
AD  - Tongji University Cancer Institute, Tongji University School of Medicine, 
      Shanghai, 200092, China.
AD  - Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 
      02114, USA.
FAU - Zhang, Han
AU  - Zhang H
AD  - Department of Cardiology, Shanghai Tenth Hospital of Tongji University, Shanghai, 
      200072, China.
FAU - Ma, Yuxia
AU  - Ma Y
AD  - Department of Internal Medicine, Cangzhou Central Hospital, Cangzhou, China.
FAU - Che, Wenliang
AU  - Che W
AD  - Department of Cardiology, Shanghai Tenth Hospital of Tongji University, Shanghai, 
      200072, China.
FAU - Hamblin, Michael R
AU  - Hamblin MR
AUID- ORCID: 0000-0001-6431-4605
AD  - Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 
      02114, USA. hamblin@helix.mgh.harvard.edu.
AD  - Department of Dermatology, Harvard Medical School, Boston, MA, 02115, USA. 
      hamblin@helix.mgh.harvard.edu.
AD  - Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, 02139, 
      USA. hamblin@helix.mgh.harvard.edu.
LA  - eng
GR  - R01 AI050875/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170303
PL  - England
TA  - Cardiol Ther
JT  - Cardiology and therapy
JID - 101634495
PMC - PMC5446820
OTO - NOTNLM
OT  - Angiotensin II receptor blockers
OT  - Blood pressure control
OT  - Combination drug treatment
OT  - Hypertension
OT  - Olmesartan medoxomil
EDAT- 2017/03/05 06:00
MHDA- 2017/03/05 06:01
PMCR- 2017/03/03
CRDT- 2017/03/05 06:00
PHST- 2017/01/17 00:00 [received]
PHST- 2017/03/05 06:00 [pubmed]
PHST- 2017/03/05 06:01 [medline]
PHST- 2017/03/05 06:00 [entrez]
PHST- 2017/03/03 00:00 [pmc-release]
AID - 10.1007/s40119-017-0087-5 [pii]
AID - 87 [pii]
AID - 10.1007/s40119-017-0087-5 [doi]
PST - ppublish
SO  - Cardiol Ther. 2017 Jun;6(1):13-32. doi: 10.1007/s40119-017-0087-5. Epub 2017 Mar 
      3.